Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.21% and 3.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.